Human Insulin-Like Growth Factor Receptor 1 in Serum: Can it be Evaluated by ELISA?
A. Margeli,L. Deneux,H. Magdelenat
DOI: https://doi.org/10.1177/172460080201700311
2002-07-01
Abstract:In human tumors the mitogenic and antiapoptotic effects of insulin-like growth factors I and II (IGF-I and IGFII) are mediated by binding of the peptides to the insulinlike growth factor receptor 1 (IGFR1) (1, 2). The measurement of IGFR1 levels in serum may reflect, as for other membrane receptors (e.g. IL-6, HER2), an accelerated turnover or a tumor-associated proteolytic activity. To our knowledge there are no quantitative data on serum IGFR1 levels, even if a commercial ELISA development kit (Cat. No. DY 391, R&D Systems, Inc., MN, USA) is available for the measurement of “natural and recombinant human IGFR1 in cell culture supernates and serum”. This ELISA was first performed according to the manufacturer’s instructions. The ELISA plate was coated with mouse antihuman IGFR1 antibody and then “blocked” to prevent any further nonspecific binding; this was followed by incubation of the antibody-coated microtiter plate wells with either calibrators or serum samples. Bound antigen was detected with a biotinylated goat anti-human IGFR1 antibody, followed by addition of streptavidin conjugated to horseradish-peroxidase (HRP) and subsequent addition of substrate. The amount of hydrolyzed substrate was assessed as the optical density determined by a microplate reader set to 450 nm with correcting wavelength at 550 nm. The detection antibody, the standard curve with serial dilutions of a standard antigen solution, and the streptavidin HRP were diluted to working concentrations in reagent diluent containing phosphate buffered saline (PBS) supplemented with fetal calf serum (FCS). The optical density measured should be proportional to the amount of specific antigen in the standard curve but proved to be extremely low under the conditions suggested by the manufacturer. In order to optimize the standard curve and increase the optical densities, we first changed two parameters: the concentration of streptavidin from the suggested dilution of 1:200 to serial dilutions of 1:150, 1:100, 1:50, 1:45, 1:40, 1:35, 1:30, 1:25 and 1:20, and the concentration of FCS in the reagent diluent. A streptavidin dilution of 1:30 was considered appropriate under the conditions of the assay, using a reagent diluent supplemented with 25% FCS. Increasing the concentration of streptavidin resulted in an increase in optical density from 0.065 to 2.81 for the highest standard concentration. In the assay protocol it was recommended to use PBS supplemented with 10-50% FCS for determination of serum samples. We used four different solutions of reagent diluent. The first contained PBS only, while the second, third and fourth contained PBS supplemented with 10%, 25%, and 40% FCS, respectively. When we decreased the FCS concentration (e.g. from 25% to 10% in the reagent diluent), the optical densities of the standard curve became extremely high. By performing different procedures we established the optimum conditions for the standard curve, using reagent diluent containing 25% FCS and streptavidin at a dilution of 1:40. With these modifications the ELISA presented intraand interassay coefficients of variation of 2.5% and 25%, respectively, for the measurement of different concentrations of IGFR1 standards diluted in an environment of FCS. Among the 68 analyzed serum samples from patients in clinical remission of prostate cancer (n=20) and patients with prostate cancer (n=48), only six (9%) presented optical densities higher than the one corresponding to the zero concentration of the standard curve. In addition, the dilution of serum samples either with the reagent diluent containing FCS or with PBS showed values similar to the average zero standard optical density. It can therefore be concluded that this ELISA cannot detect IGFR1 levels in human serum, although it can detect concentrations of antigens as low as 100 pg/mL in culture medium. We further looked for the presence of a factor potentially masking the receptor in serum samples and applied a standard spiking procedure. When fixed quantities of standard (0.5 or 1.0 ng/mL) containing the reagent diluent supplemented with FCS were added to samples (1:2 dilution), the optical densities were not increased. When samples were diluted in PBS and supplemented with a known quantity of standard, the optical densities increased with PBS dilution, but always less than expected for the corresponding standard (Fig.1). IGFR1 levels reThe International Journal of Biological Markers, Vol. 17 no. 3, pp. 215-216 © 2002 Wichtig Editore